Low Molecular Weight Heparin Reduces sVCAM-1 and Lung Congestion In a Murine Model of Sickle Cell Disease
| Autor: | Yihe Guo, Joshua J. Field, J. Paul Scott, Nancy J. Wandersee, Thomas D. Foster, Cheryl A. Hillery |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry Immunology Low molecular weight heparin Cell Biology Hematology Heparin medicine.disease Biochemistry Sickle cell anemia Proinflammatory cytokine Tissue factor Endocrinology Thrombin Internal medicine medicine Thromboplastin business Fibrinolytic agent medicine.drug |
| Zdroj: | Blood. 116:1635-1635 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v116.21.1635.1635 |
| Popis: | Abstract 1635 There is evidence for increased levels of procoagulant proteins, thrombin generation and tissue factor activity in individuals with sickle cell disease. Both thrombin and tissue factor also have potent proinflammatory effects that likely further contribute to the vascular dysfunction and organ injury observed in sickle cell disease. In this study, we examine the effect of the LMW heparin, enoxaparin, on markers of vascular injury and inflammation in the Berkeley mouse model of severe sickle cell disease (HbSS mice). HbSS mice or control HbAA mice (that exclusively express normal human HbA) were treated with continuous subcutaneous infusion of enoxaparin (10 mg/kg/day) or saline for 14 days using a surgically implanted Alzet pump (n=12-14 mice per group). Blood was collected at baseline and following 14 days enoxaparin therapy. Anesthetized animals were perfused with PBS at constant physiologic pressure (80 mmg Hg) and lung and liver collected for pathologic analyses. Enoxaparin-treated mice had steady state LMW heparin levels of 0.45 ± 0.17 anti-Xa U/mL compared to Disclosures: Field: Novartis: Honoraria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|